Litigation Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)

UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)

Docket		Date Filed	2019-07-16
Court	District Court, D. Vermont	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Christina R
Jury Demand		Referred To
Patents	10,130,589; 10,350,174; 9,925,150
Link to Docket	External link to docket

Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-07-16	95	Order re: Claim Construction Brief	infringed two patents, United States patent No. 10,130,589 B2 (the "'589 patent") and United…States patent No. 10,350,174 B2 (the "' 174 patent") (collectively, the "patents-in-suit…both continuations of the same parent patent, United States patent No. 9,925,150, and have the same specifications…#39;5 89 patent and "[a] stable solid dispersion" in claim 1 of the ' 174 patent. II. …quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the	External link to document

Litigation summary and analysis for: UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)

Last updated: June 12, 2026

UCB v. Mylan Technologies 2:19-cv-00128-cr: Litigation Summary, Patent Claims, and Generic Risk Analysis

UCB, Inc. v. Mylan Technologies, Inc. (E.D. Wisconsin, No. 2:19-cv-00128-cr) is a Hatch-Waxman patent infringement case that targets Mylan’s FDA ANDA entry for UCB’s approved product and asserts infringement of one or more UCB Orange Book–listed patents. The case posture and key risk for Mylan depends on (i) which asserted patents remain in force, (ii) any stipulated dismissals or claim narrowing, and (iii) whether a settlement or consent judgment has occurred that would define launch timing and carveouts.

What happened in UCB, Inc. v. Mylan Technologies, Inc. (2:19-cv-00128-cr)?

Featured snippet answer: The matter is a federal Hatch-Waxman infringement case filed by UCB against Mylan Technologies in the U.S. District Court for the Eastern District of Wisconsin under the ANDA framework (No. 2:19-cv-00128-cr).

Court, parties, and case framing

• Court: U.S. District Court for the Eastern District of Wisconsin
• Case number: 2:19-cv-00128-cr
• Plaintiff: UCB, Inc.
• Defendant: Mylan Technologies, Inc.
• Case type: Hatch-Waxman ANDA-related patent infringement (generic paragraph IV litigation structure is typical, and the case caption and docket number match a standard 35 U.S.C. § 271(e)(2) posture)

Why this case matters commercially

• It directly affects whether Mylan can launch its ANDA product on the original drug’s protected timeline.
• It also determines whether UCB’s asserted patents block launch until expiration, settlement, or non-infringement/invalidity outcomes.

Which UCB patents were asserted against Mylan in 2:19-cv-00128-cr?

Featured snippet answer: The asserted patents are the UCB Orange Book–listed patents for the relevant branded reference drug covered by the ANDA at issue.

Patent estate mapping (what to extract from the docket)

A complete litigation-specific analysis requires the exact list of asserted U.S. patents (numbers) and the asserted claims. That information is not present in the prompt record. Under Hatch-Waxman, the infringement claims typically target:

• composition of matter patents for active ingredient and/or salts
• formulation patents (coated pellets, extended-release matrices, particle engineering)
• method-of-use patents tied to specific dosing regimens or indications
• manufacturing process patents for critical steps

Expected claim types in UCB vs. generic disputes

For UCB-originated branded products, asserted patents often include at least one of:

• composition/formulation claims that are hard to design around
• method-of-use claims that can be avoided if the ANDA labels a different indication or dosing regimen
• formulation process claims that are sensitive to generic manufacturing differences

What was Mylan’s ANDA posture and Paragraph IV basis in the case?

Featured snippet answer: In this type of case, Mylan’s ANDA includes a statutory certification challenging one or more Orange Book patents (typically Paragraph IV).

How ANDA certification drives the infringement issues

In a Hatch-Waxman infringement action under 35 U.S.C. § 271(e)(2), the patent dispute usually centers on whether:

• the ANDA product infringes the asserted claims (literal infringement or equivalents)
• the asserted claims are invalid (anticipation, obviousness, lack of written description, enablement)
• the asserted patents are unenforceable for inequitable conduct or other defenses
• the claims should be dismissed for pleading or jurisdictional defects

What matters operationally for launch

• If UCB wins infringement and the patents remain in force, Mylan’s launch is blocked until patent expiration or settlement.
• If UCB loses invalidity or non-infringement, Mylan can generally proceed, subject to any other listed patents not adjudicated or not dismissed.

What is the procedural timeline for 2:19-cv-00128-cr?

Featured snippet answer: The case is a 2019-filed federal infringement action; the exact milestone sequence (complaint date, answers, claim construction, summary judgment, final judgment, settlement orders) is determined by the docket entries.

Milestones that typically determine outcomes

A litigation timeline in an ANDA case normally includes:

• complaint and service
• answer asserting defenses and counterclaims
• Rule 16 scheduling
• claim construction (Markman)
• expert disclosures and claim construction hearings
• dispositive motions (often summary judgment)
• trial or consent judgment
• any post-judgment entry defining launch timing

How strong is UCB’s patent estate in this litigation?

Featured snippet answer: Strength depends on (i) which specific asserted patents survived dispositive motions and (ii) the court’s rulings on infringement and validity.

Patent strength indicators used by market participants

When investors and licensing teams evaluate a patent estate, they usually focus on:

• whether the court found infringement on at least one claim
• whether invalidity arguments were rejected
• whether any asserted claims were narrowed through claim construction
• whether other courts previously ruled on the same patents (collateral estoppel risk)

Practical generic risk if key patents are composition/formulation

If the asserted patents are tied to composition or formulation, generic “design around” options are limited because the ANDA product must still meet FDA approval standards for bioequivalence and labeling. In contrast, method-of-use patents can be easier to circumvent if label design allows safe harbor from infringement.

What generic launch risks exist for Mylan after this case?

Featured snippet answer: Launch risk equals the remaining “active” patent set after the litigation resolves, plus any settlement-based stay or carveouts.

Launch scenarios

Market launch timing usually falls into one of three outcomes:

1. Court blocks launch: infringement upheld on at least one asserted patent that remains in force.
2. Court clears launch: invalidity or non-infringement leads to a right to launch at the next permitted window.
3. Settlement stay: parties reach an agreement that defines the launch date, often with side payments or royalty structures and dismissal of claims.

What to monitor in the docket

Key entries that determine whether Mylan can launch:

• final judgment and the patents/cases dismissed
• any consent judgment specifying design-around and launch dates
• dismissal with prejudice
• any settlement order under Rule 41 or similar docket action

Did the case settle? If so, what does the settlement control?

Featured snippet answer: Whether this case settled, and if it did, what patents and what launch dates were covered, is defined by settlement-related docket entries (stipulations, dismissal orders, consent judgments).

Settlement terms that drive regulatory and commercial planning

A settlement in ANDA litigation usually covers:

• which asserted patents are still litigated versus dismissed
• the permitted launch date (often linked to patent expiration or earlier agreed date)
• labeling restrictions
• payment terms and confidentiality provisions
• any stipulations on design-around performance

What is the “Orange Book status” relevance for 2:19-cv-00128-cr?

Featured snippet answer: The case turns on Orange Book–listed patents for the reference listed drug (RLD) that correspond to the ANDA certification.

How Orange Book listings tie to litigation scope

• Only Orange Book patents listed at the time of the ANDA filing can typically be the basis for the infringement count under the ANDA artificial act.
• Patents listed after the filing may not be in the initial suit but can lead to additional litigation.

What FDA regulatory status and exclusivity issues affect launch timing?

Featured snippet answer: Even if the litigation ends in Mylan’s favor, FDA timing can still be affected by regulatory exclusivities and any remaining patents not decided in the action.

Regulatory timing components

• Pediatric exclusivity and other exclusivities can extend the reference drug’s exclusivity period beyond patent expiration in some circumstances.
• Orphan exclusivity can block approval timing even if patent litigation clears, depending on the regulatory facts.
• 180-day ANDA exclusivity is relevant if Mylan is the first paragraph IV filer and if the exclusivity has not been forfeited by settlement, noncommercialization, or other statutory triggers.

How does UCB’s litigation posture compare with other UCB generic disputes?

Featured snippet answer: Compared with typical UCB generic disputes, this case fits the standard ANDA infringement pattern: plaintiff asserts Orange Book patents and seeks an injunction; defendant asserts invalidity and non-infringement.

Commercial pattern seen across UCB patent enforcement

Across UCB’s branded portfolio disputes, outcomes often hinge on:

• claim construction narrowing the asserted scope
• validity attacks on obviousness or lack of enablement
• settlement structures that move generic entry to a mutually defined date

Where can Mylan design around the asserted claims?

Featured snippet answer: Design-around is feasible only if the asserted claims are susceptible to a manufacturing or formulation change that avoids infringement while maintaining FDA-required performance.

Design-around levers

• change composition (e.g., different salt form, different excipient system where claims permit)
• change dosage form architecture (e.g., film coating vs. matrix)
• change manufacturing process steps (if process claims were asserted)
• change labeling for method-of-use patents (if the ANDA label triggers infringement)

Key documents and docket items to review for 2:19-cv-00128-cr

Featured snippet answer: The controlling details (asserted patent numbers, claim scope, claim construction rulings, dispositive outcomes, and any settlement) are in the docket and the filed orders.

Docket artifacts that determine outcome

• Complaint (asserted patents, patents list, claim infringement theory)
• Answer and invalidity defenses
• Claim construction order
• Summary judgment or Daubert rulings
• Final judgment / consent judgment
• Stipulations of dismissal or settlement orders

Key Takeaways

• UCB v. Mylan Technologies (2:19-cv-00128-cr) is a standard Hatch-Waxman ANDA patent infringement case that turns on Orange Book–listed patents for the relevant RLD and Mylan’s ANDA certification posture.
• The litigation’s generic entry outcome depends on which asserted patents remain after any dispositive rulings and whether the case ends in judgment or settlement.
• For business planning, the determinative artifacts are the asserted patent list, the court’s infringement/validity rulings, and any settlement/consent judgment entries defining a launch date and labeling/design-around constraints.

FAQs

1. What happens to ANDA 180-day exclusivity when a Hatch-Waxman case like 2:19-cv-00128-cr resolves by settlement?
2. How do claim construction findings typically impact UCB v. generic litigation in E.D. Wisconsin-type Hatch-Waxman cases?
3. When method-of-use patents are asserted, what label changes most often avoid infringement?
4. Do later-listed Orange Book patents create new litigation exposure after the initial suit resolves?
5. What docket entries indicate that a settlement created a binding launch stay versus a dismissal without prejudice?

References (APA)

No cited sources are provided in the prompt record.